Melatonin, environmental light, and breast cancer

Area of Science:

• Endocrinology
• Oncology
• Chronobiology

Background:

• Increased breast cancer incidence in night-shift workers suggests a role for melatonin suppression.
• Melatonin deficiency or light-induced suppression is hypothesized to contribute to cancer development.

Purpose of the Study:

• To investigate the anticarcinogenic effects of melatonin in breast cancer.
• To explore melatonin's mechanisms of action, particularly in estrogen receptor-positive cells.

Main Methods:

• Experimental models (7,12-dimethylbenz[a]anthracene, N-methyl-N-nitrosourea) were used to study melatonin's effect on cancer development.
• In vitro studies utilized the MCF-7 human breast cancer cell line to examine melatonin's cellular mechanisms.
• Analysis of gene expression, protein modulation, cell proliferation, and metastatic capacity was performed.

Main Results:

• Melatonin demonstrated efficacy in reducing cancer development in experimental models.
• In vitro, melatonin suppressed estrogen receptor (ER) gene expression and modulated related proteins in MCF-7 cells.
• Melatonin inhibited cell proliferation, impaired metastatic capacity, and acted as an endogenous antiestrogen at physiological concentrations.
• Melatonin also inhibited aromatase activity, reducing estrogen formation.

Conclusions:

• Melatonin exhibits significant anticarcinogenic properties against breast cancer, especially in ER-positive subtypes.
• Low circulating melatonin levels in ER-positive breast cancer patients support the melatonin hypothesis.
• Endogenous melatonin secretion may contribute to the benefits of interventions like meditation for breast cancer patients.